{"id":22330,"date":"2019-12-19T09:43:31","date_gmt":"2019-12-19T08:43:31","guid":{"rendered":"https:\/\/qlinea.com\/management\/"},"modified":"2026-01-20T08:37:15","modified_gmt":"2026-01-20T07:37:15","slug":"management","status":"publish","type":"page","link":"https:\/\/qlinea.com\/us\/investor-relations\/corporate-governance\/management\/","title":{"rendered":"Management"},"content":{"rendered":"
\r\n
\r\n
\r\n

Management<\/h1>\r\n

The CEO & Managing Director is appointed by the board and is responsible for the Company\u2019s day-to-day management in accordance with the board\u2019s guidelines and instructions.<\/p>\n

The CEO & Managing Director is responsible for keeping the board informed about the Company\u2019s performance and reporting significant deviations from established business plans and about events with a major impact on the Company\u2019s performance and operations, and for providing the board with relevant decision support in regard to, for example, establishments, investments and other strategic issues. Company management, headed by the Company\u2019s CEO Stuart Gander, consists of people in charge of Q-linea\u2019s key business areas.<\/p>\n

Current holdings.<\/p>\n<\/h3>\r\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
\n
\n
Stuart Gander<\/h6>\n
CEO & President<\/h6>\n

Born:<\/strong> 1978<\/p>\n

President since 1 March 2024<\/p>\n

Stuart Gander has worked in the healthcare industry since 2006, advising companies across all sectors while serving with The Boston Consulting Group, where he was Managing Director & Partner. He specialized in medical technologies, working across a wide variety of sectors with an emphasis on medical diagnostics. He has experience working in most major healthcare markets around the world, having lived in nearly equal measure in Europe and North America. Prior to joining Q-linea, he was a member of the executive team at StatLab, a US-based leader in histology, where he held a variety of leadership roles in operations, sales & marketing, R&D and managing its international subsidiaries.<\/p>\n

Education<\/strong>: Graduated with honours from Queen\u2019s University School of Commerce (now Smith) in Kingston, Canada (2000).<\/p>\n<\/div>\n

\n

Other ongoing assignments<\/strong>: Stuart Gander has no other current assignments.<\/p>\n

Holdings in the Company<\/strong>: Stuart Gander owns 53,100 shares and 2,343,000 stock options in the Company. Each stock option entitles to 0.00165 shares. \u00a0Stuart also owns 40,000 call options in the Company, issued by Investment AB \u00d6resund.<\/p>\n<\/div>\n<\/div>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
Anders Ljunggren
\n<\/strong><\/h6>\n
Managing Director<\/h6>\n

Born<\/strong>: 1981
\nEmployed by the company since 2022, Managing Director since March 1 2024<\/p>\n

Anders Ljunggren has extensive experience in engineering project management, having worked at innovative R&D companies in industries like medical devices, industrial applications, consumer electronics, and space technology for the past 15 years. He has a track record of successfully managing B2B and in-house development projects, utilizing cross-functional team management skills and deep understanding of product development. At Q-linea he was responsible for setting up and leading the project management office and establish a portfolio management process as well as a matrix organisation before being promoted to Managing Director.<\/p>\n

Education:<\/strong> Masters of Science in Materials Engineering Physics, Uppsala University, 2007
\nOther ongoing assignments:<\/strong> Owner of Coego Consulting AB and Introspection AB. Member of the board of the private estate company BKFAB<\/p>\n

Holdings in the Company<\/strong>:<\/strong> Anders Ljunggren owns 2,700 shares and 200,000 stock options in the Company. Each stock option entitles to 0.00165 shares.<\/p>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
\n
Christer Samuelsson<\/h6>\n<\/div>\n
\n
CFO<\/h6>\n<\/div>\n
\n

Born<\/strong>: 1962
\nChief Financial Officer and Investor Relations since 1 May, 2023.<\/p>\n

Christer Samuelsson has 20 years of experience as CFO in various industries, incl. Life Science, manufacturing industries, telecom and renewable energy, both listed and unlisted companies. In addition, he has more than ten years of experience from the financial sector.<\/p>\n

Education<\/strong>: BSc in Business administration and Economics, Uppsala University (1987).<\/p>\n

Other ongoing assignments<\/strong>: Christer Samuelsson has no other current assignments.<\/p>\n

Holdings in the Company<\/strong>: Christer Samuelsson owns 3,838 shares and 170,000 stock options in the company. Each stock option entitles to 0.00165 shares.<\/p>\n<\/div>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
\n
Franco Pellegrini<\/h6>\n<\/div>\n
\n
VP Sales, EMEA<\/strong><\/h6>\n<\/div>\n
\n

Born<\/strong>: 1968
\nEmployed by the Company since 2023<\/p>\n

Franco Pellegrini has more than 20 years of commercial experience in different segments of the Healthcare Market like Cardiac surgery, Radiology and Ultrasound, Minimally Invasive Surgery and Microbiology in both Europe and Unites States.<\/p>\n

Other ongoing assignments<\/strong>: Franco Pellegrini has no other current assignments.<\/p>\n

Education<\/strong>: Law Degree from Universit\u00e0 Statale di Milano, Italy (1992).<\/p>\n

Holdings in the Company<\/strong>: Franco Pellegrini owns 1,000 shares and 170,000 stock options in the company. Each stock option entitles to 0.00165 shares.<\/p>\n<\/div>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
\n
Henrik Jacobsson<\/h6>\n<\/div>\n
\n
Chief Operating Officer<\/h6>\n<\/div>\n
\n

Born<\/strong>: 1969
\nEmployed by the Company as Production Manager since 2021, Chief Operating Officer since 2022.<\/p>\n

Henrik has more than 25 years of experience in leading positions mainly in operations and production. He helped create the convenience food concept and the company Gooh where he was responsible for building up the production and logistics operations. This work provided good experience in creating and scaling up the factory and organization. Henrik has also been production director at Lantm\u00e4nnen Cerealia and CEO of Swedish Meat’s subsidiary Esca Food Solutions.<\/p>\n

Education<\/strong>: MSc in Industrial Economics, Link\u00f6ping University (1995).<\/p>\n

Other ongoing assignments<\/strong>: Board member of Jacobson Energi AB, Sk\u00e5nings \u00c5saka Vind AB and Vida Vind AB.<\/p>\n

Holdings in the Company<\/strong>: Henrik Jacobson owns 3,155 shares and 170,000 stock options in the Company. Each stock option entitles to 0.00165 shares.<\/p>\n<\/div>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
Victoria Lerneryd
\nManager QA\/RA<\/h6>\n

Born<\/strong>: 1984
\nEmployed by the Company since 2020, Manager QA\/RA since 2020<\/p>\n

Victoria Lerneryd has over 12 years of experience in quality assurance and regulatory affairs for medical devices, including developing and maintaining quality management systems, preparing regulatory product documentation, and regulatory reviews and applications. She has previously held positions as Quality Manager at St. Jude Medical and Quality & Regulatory Affairs Manager at Cavidi. These roles have included responsibility for compliance with regulatory requirements from product development to production and monitoring of products released to the market.<\/p>\n

Education<\/strong>: MSc in Chemical Engineering, Uppsala University (2009).
\nOther ongoing assignments<\/strong>: Victoria Lerneryd has no other current assignments.
\nHoldings in the Company<\/strong>: Victoria Lerneryd owns 446 shares and 170,000 stock options in the company. Each stock option entitles to 0.00165 shares.<\/p>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
Natalie Brown
\nGlobal Marketing Director<\/h6>\n

Born<\/strong>: 1986
\nEmployed by the Company since 2024, Global Marketing Director since 1 April 2025<\/p>\n

Natalie Brown is passionate about improving healthcare outcomes. She began her career in a breast cancer research lab and later worked on the implantable ports marketing team at C.R. Bard (now BD). Her experience includes working with NGOs in the US, Mexico, and Tanzania, focused on HIV\/AIDS prevention and treatment, free clinic management, and refugee assistance. Prior to joining Q-linea, she was employed by Accelerate Diagnostics for six years, where she held a variety of marketing roles.<\/p>\n

Education<\/strong>: Bachelor of Science in molecular and cellular biology, University of Arizona (2008); Master of Business Administration with healthcare management concentration, University of Arizona (2017).<\/p>\n

Other ongoing assignments<\/strong>: Natalie Brown has no other current assignments.<\/p>\n

Holdings in the Company<\/strong>: Natalie Brown owns 966 shares and 30,000 stock options in the company. Each stock option entitles to 0.00165 shares.<\/p>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n

\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n
Ylva Molin
\nManager, Assay<\/h6>\n

Born<\/strong>: 1981
\nEmployed by the Company since 2012, Manager Assay since January 1 2026<\/p>\n

Ylva Molin has over ten years of experience in product development in medical technology through several leading roles at Q-linea. Ylva possesses a deep and solid knowledge of the company’s products. Previously, Ylva worked at Clinical Microbiology at Uppsala University Hospital. This combination of industrial and clinical backgrounds contributes valuable scientific and operational expertise.<\/p>\n

Education<\/strong>: PhD in infectious diseases, Uppsala University 2010. Biomedicine Program, Uppsala University, 2005.<\/p>\n

Other ongoing assignments<\/strong>: Ylva Molin has no other ongoing assignments.<\/p>\n

Holdings in the Company<\/strong>: Ylva Molin owns 891 shares and 50,000 stock options in the Company. Each stock option entitles to 0.00165 shares.<\/p>\n <\/div>\r\n <\/div>\r\n<\/section>\r\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":22348,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-22330","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/comments?post=22330"}],"version-history":[{"count":9,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22330\/revisions"}],"predecessor-version":[{"id":29692,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22330\/revisions\/29692"}],"up":[{"embeddable":true,"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/pages\/22348"}],"wp:attachment":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/media?parent=22330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}